10.1002/med.20142 21 MohsinS.BaniyasM
There is a small risk of developing pancreatitis, a serious inflammation of the pancreas, necessitating monitoring for related symptoms (Marso et al., 2016)
Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have individually been shown to reduce cardiovascular and kidney outcomes in patients with T2DM, with a low hypoglycemia risk [3, 4]
This can be an excellent treatment for facet arthritis often initiated following whiplash type injuries
These agents bind to GLP-1 receptors expressed throughout the body, including pancreatic beta cells, the gastrointestinal tract, and central nervous system regions involved in appetite regulation
Eli Lilly ran two Phase III studies of people living with obesity and moderate-to-severe obstructive sleep apnea for 52 weeks each